VBIV - VBI Vaccines, Inc. Year-over-year net earnings per share growth for the last 12 months

Quarterly EPS progress demonstrates the profit dynamics of VBI Vaccines Inc. (VBIV), where the 0.00 mark reflects the latest data. This chart captures a technical pause resulting from financial restructuring and an R&D freeze. VBI Vaccines Inc. (VBIV) generates revenue through the sale of its Hepatitis B vaccine and partnership grants. The potential for share price growth now relies on the success of its glioblastoma therapy and new contracts.
Financial and market metric breakdowns for vbivaccines.com (VBIV)

The strong pricing power of VBI Vaccines Inc. (VBIV), driven by the uniqueness of its eVLP platform, should translate into growth in net earnings per share. By analyzing the quarterly shift in earnings per share, an investor assesses the EPS trend relative to the previous period, which allows for the mathematical confirmation of innovation monetization efficiency and prevents capital from being frozen in an overvalued asset.